

해외 바이오의약품 임상 현황 (2020.09.28~2020.10.04)

한국바이오의약품협회, 2020.10.6.
출처: ClinicalTrials.gov

○ 미국 98건

| NCT Number | Title | Conditions | Interventions | Sponsor/Collaborators | Phases |
|-------------|---|--|--|--|---------------------|
| NCT04552704 | CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study | Advanced Malignant Solid Neoplasm | Biological: CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc[Drug: Placebo Administration | Tianhong Li[National Cancer Institute (NCI)]Oncolmmune, Inc.[University of California, Davis | Phase 1 Phase 2 |
| NCT04548583 | Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis | Crohn Colitis | Drug: remesetemcel-L[Other: Placebo | The Cleveland Clinic[Mesoblast, Inc. | Phase 1 Phase 2 |
| NCT04543994 | Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC) | Ulcerative Colitis | Drug: Remestemcel-L[Other: Placebo | The Cleveland Clinic[Mesoblast, Inc. | Phase 1 Phase 2 |
| NCT04519697 | Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease | Rectovaginal Fistula[Crohn Disease][Crohn Disease of Vulva][Rectolabial; Fistula | Drug: Mesenchymal Stem Cells[Other: Placebo | The Cleveland Clinic | Phase 1 Phase 2 |
| NCT04519684 | Study of Mesenchymal Stem Cells for the Treatment of Ileal Pouch Fistula's in Participants With Crohn's Disease | Ileal Pouch[Crohn Disease | Drug: Mesenchymal stem cells[Other: Placebo | The Cleveland Clinic | Phase 1 Phase 2 |
| NCT04519671 | Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease | Perianal Crohn Disease[Perianal Fistula][Crohn Disease | Drug: Mesenchymal Stem Cells[Other: Placebo | The Cleveland Clinic | Phase 1 Phase 2 |
| NCT04512261 | TOPAZ: Tucatinib in Combination With Pembrolizumab And Trastuzumab in Women With HER2-Positive Breast Cancer Brain Metastases | Breast Cancer[Brain Metastases][HER2-positive Breast Cancer][CNS Disease | Drug: Tucatinib[Drug: Pembrolizumab][Drug: Trastuzumab | Reva Basho[Merck Sharp & Dohme Corp.][Seattle Genetics, Inc.][Cedars-Sinai Medical Center | Phase 1 Phase 2 |
| NCT03851081 | Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia | Allogeneic Hematopoietic Stem Cell Transplantation Recipient[Blasts 5 Percent or More of Bone Marrow Nucleated Cells][Blasts 5 Percent or More of Peripheral Blood White Cells][CD22 Positive][Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells][Lymphoblasts 20 Percent or More of Peripheral Blood White Cells][Recurrent B Acute Lymphoblastic Leukemia][Refractory B Acute Lymphoblastic Leukemia | Biological: Inotuzumab Ozogamicin[Other: Quality-of-Life Assessment][Drug: Vincristine Sulfate Liposome | Roswell Park Cancer Institute[Pfizer | Phase 1 Phase 2 |
| NCT03735589 | Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Stage II Fallopian Tube Cancer AJCC v8[Stage II Ovarian Cancer AJCC v8][Stage II Primary Peritoneal Cancer AJCC v8][Stage IIA Fallopian Tube Cancer AJCC v8][Stage IIA Ovarian Cancer AJCC v8][Stage IIA Primary Peritoneal Cancer AJCC v8][Stage IIB Fallopian Tube Cancer AJCC v8][Stage IIB Ovarian Cancer AJCC v8][Stage IIB Primary Peritoneal Cancer AJCC v8][Stage III Fallopian Tube Cancer AJCC v8][Stage III Ovarian Cancer AJCC v8][Stage III Primary Peritoneal Cancer AJCC v8][Stage IIIA Fallopian Tube Cancer AJCC v8][Stage IIIA Ovarian Cancer AJCC v8][Stage IIIA Primary Peritoneal Cancer AJCC v8][Stage IIIA1 Fallopian Tube Cancer AJCC v8][Stage IIIA1 Ovarian Cancer AJCC v8][Stage IIIA2 Fallopian Tube Cancer AJCC v8][Stage IIIA2 Ovarian Cancer AJCC v8][Stage IIIB Fallopian Tube Cancer AJCC v8][Stage IIIB Ovarian Cancer AJCC v8][Stage IIIB Primary Peritoneal Cancer AJCC v8][Stage IIIC Fallopian Tube Cancer AJCC v8][Stage IIIC Ovarian Cancer AJCC v8][Stage IIIC Primary Peritoneal Cancer AJCC v8][Stage IV Fallopian Tube Cancer AJCC v8][Stage IV Ovarian Cancer AJCC v8][Stage IV Primary Peritoneal Cancer AJCC v8][Stage IVA Fallopian Tube Cancer AJCC v8][Stage IVA Ovarian Cancer AJCC v8][Stage IVA Primary Peritoneal Cancer AJCC v8][Stage IVB Fallopian Tube Cancer AJCC v8][Stage IVB Ovarian Cancer AJCC v8][Stage IVB Primary Peritoneal Cancer AJCC v8 | Biological: Alpha-type-1 Polarized Dendritic Cells[Biological: Autologous Natural Killer Cell-like CTLs | Roswell Park Cancer Institute[National Cancer Institute (NCI) | Phase 1 Phase 2 |
| NCT03678467 | Evaluation of EpiBone-CMF for Mandibular Ramus Reconstruction | Mandible Tumor[Mandibular Injuries][Mandible; Deformity | Combination Product: EB-CMF | Epibone, Inc. | Phase 1 Phase 2 |
| NCT03597594 | Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID) | Severe Combined Immunodeficiency | Drug: Anti-thymocyte globulin (rabbit)[Drug: Busulfan][Drug: Fludarabine][Drug: Thiotepal][Device: CliniMACS][Other: Donor Lymphocyte Infusion | St. Jude Children's Research Hospital | Phase 1 Phase 2 |
| NCT04263831 | LOW DOSE IL-2 FOR THE TREATMENT OF CROHN'S DISEASE | Crohn Disease | Drug: Interleukin-2 (aldesleukin). | Boston Children's Hospital | Phase 1 Phase 2 |
| NCT04573140 | A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM) | Adult Glioblastoma | Biological: Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs) | University of Florida[Pacific Pediatric Neuro-Oncology Consortium][University of California, San Francisco][CureSearch | Phase 1 |
| NCT04572451 | Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors | Melanoma[Carcinoma, Renal Cell][Unresectable Solid Tumors | Drug: nivolumab[Drug: BMS-986253][Radiation: Stereotactic Body Radiotherapy (SBRT) | Jason J. Luke, MD[Bristol-Myers Squibb][University of Pittsburgh | Phase 1 |
| NCT04571203 | Kidney and Hematopoietic Cell Transplants Using a Regimen to Promote Hematopoietic Cell Engraftment | Immune Tolerance | Biological: Combined Deceased Donor Kidney and Hematopoietic Cell Transplants | Stanford University | Phase 1 |
| NCT04564846 | A Phase 2b Study to Evaluate the Effect of ORMD-0801 in Patients With Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2 | Drug: ORMD-0801[Other: Placebo | Oramed, Ltd. | Phase 2 |
| NCT04547777 | Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma | Glioma, Malignant | Drug: D2C7-IT[Drug: 2141-V11 | Darell Bigner[Rockefeller University][Duke University | Phase 1 |
| NCT04535817 | Xolair Interventional Study in ASD Patients With Comorbid Atopy | Autism Spectrum Disorder[Atopy | Drug: Omalizumab Injection [Xolair] | Beth Israel Deaconess Medical Center[Novartis | Phase 1 |
| NCT04528719 | A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults Aged 18 to 49 Years and in Children Aged 12 to 36 Months Who Are Respiratory Syncytial Virus Seropositive | Respiratory Syncytial Virus | Biological: mRNA-1345[Drug: Placebo | ModernaTX, Inc. | Phase 1 |

해외 바이오의약품 임상 현황 (2020.09.28~2020.10.04)

한국바이오의약품협회, 2020.10.6.
출처: ClinicalTrials.gov

| | | | | | |
|-------------|---|---|---|--|---------|
| NCT04526288 | CPX-351 Versus Immediate Donor Stem Cell Transplant for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease | Acute Myeloid Leukemia Myelodysplastic Syndrome With Excess Blasts-2 Myeloid Neoplasm | Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Liposome-encapsulated Daunorubicin-Cytarabine | Fred Hutchinson Cancer Research Center Jazz Pharmaceuticals | Phase 2 |
| NCT04521114 | Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis(NASH) | Nonalcoholic Steatohepatitis (NASH) | Drug: leronlimab Drug: Placebos | CytoDyn, Inc. Amarex Clinical Research | Phase 2 |
| NCT04520711 | Study of Adoptively Transferred, Gene-engineered T Cells With CD40 Activation and PD-1 Blockade in Incurable Cancers | Malignant Epithelial Neoplasms | Biological: TCR-transduced T cells Drug: CDX-1140 Drug: Pembrolizumab | Providence Health & Services | Phase 1 |
| NCT04517851 | Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis | Myelofibrosis Transformation in Essential Thrombocythemia Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase Primary Myelofibrosis | Biological: Elotuzumab Other: Questionnaire Administration | M.D. Anderson Cancer Center National Cancer Institute (NCI) | Phase 1 |
| NCT04511078 | Phase II Pantumumab-IRDye800 in Head & Neck Cancer | Head and Neck Cancer | Drug: Pantumumab-IRDye800 | University of Alabama at Birmingham | Phase 2 |
| NCT04506073 | Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for iPD | Parkinson's Disease | Drug: MSC+placebo Drug: MSC Drug: Placebo | The University of Texas Health Science Center, Houston Michael J. Fox Foundation for Parkinson's Research | Phase 2 |
| NCT04496219 | Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer | Bladder Urothelial Carcinoma In Situ Recurrent Bladder Urothelial Carcinoma Stage 0a Bladder Cancer AJCC v8 Stage 0is Bladder Cancer AJCC v8 Stage I Bladder Cancer AJCC v8 Superficial Bladder Urothelial Carcinoma | Device: Acupuncture Therapy Biological: BCG Solution Other: Best Practice Other: Quality-of-Life Assessment Other: Questionnaire Administration | Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) | Phase 2 |
| NCT04489420 | Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM | Astrocytoma, Grade IV Giant Cell Glioblastoma Glioblastoma Multiforme Cyclophosphamide Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Molecular Mechanisms of Pharmacological Action Antiviral Agents Anti-infective Agents Analgesics, Non-narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents | Biological: CYNK001-IV Biological: CYNK001-IT | Celularity Incorporated | Phase 1 |
| NCT04484077 | hCT-MSC Infusion in Adults With Autism Spectrum Disorder | Autism Spectrum Disorder Autism | Biological: hCT-MSC | Joanne Kurtzberg, MD The Marcus Foundation Duke University | Phase 1 |
| NCT04482933 | HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma | Neoplasms High Grade Glioma Glioblastoma Multiforme Malignant Glioma of Brain Anaplastic Astrocytoma of Brain High-grade Glioma Anaplastic Glioma Giant Cell Glioblastoma | Drug: Biological G207 | University of Alabama at Birmingham Treovir, LLC | Phase 2 |
| NCT04472429 | Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UIM-303/InterAACT 2). | Squamous Cell Carcinoma of the Anal Canal | Drug: carboplatin Drug: paclitaxel Drug: retifanlimab | Incyte Corporation | Phase 3 |
| NCT04471974 | ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | Castration-Resistant Prostate Carcinoma Metastatic Prostate Adenocarcinoma Metastatic Prostate Small Cell Carcinoma Stage IV Prostate Cancer AJCC v8 Stage IVA Prostate Cancer AJCC v8 Stage IVB Prostate Cancer AJCC v8 | Drug: BET Bromodomain Inhibitor ZEN-3694 Drug: Enzalutamide Biological: Pembrolizumab | Rahul Aggarwal Zenith Epigenetics Merck Sharp & Dohme Corp. U.S. Army Medical Research and Development Command University of California, San Francisco | Phase 2 |
| NCT04466475 | Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma | CD38 Positive Plasma Cell Myeloma | Biological: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10 Drug: Melphalan Procedure: Peripheral Blood Stem Cell Transplantation | Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) National Institutes of Health (NIH) | Phase 1 |
| NCT04465643 | Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor | Nerve Sheath Tumors | Drug: Nivolumab Drug: Ipilimumab | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bristol-Myers Squibb | Phase 1 |
| NCT04462328 | Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma | Primary Central Nervous System Lymphoma Secondary Central Nervous System Lymphoma | Drug: Durvalumab Drug: Acalabrutinib | Washington University School of Medicine AstraZeneca | Phase 1 |
| NCT04456413 | Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection | COVID-19 | Biological: Convalescent Plasma Other: Best Supportive Care | Hackensack Meridian Health | Phase 2 |
| NCT04454489 | Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition | Advanced Head and Neck Squamous Cell Carcinoma Recurrent Head and Neck Squamous Cell Carcinoma Metastatic Head-and-neck Squamous-cell Carcinoma | Drug: Pembrolizumab (immunotherapy) Radiation: Quad-shot palliative radiotherapy | Wake Forest University Health Sciences National Cancer Institute (NCI) | Phase 2 |
| NCT04450173 | Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma | Ann Arbor Stage II Follicular Lymphoma Ann Arbor Stage III Follicular Lymphoma Ann Arbor Stage IV Follicular Lymphoma Grade 1 Follicular Lymphoma Grade 2 Follicular Lymphoma Grade 3a Follicular Lymphoma | Drug: Ibrutinib Biological: Obinutuzumab Drug: Venetoclax | Joseph Tuscano National Cancer Institute (NCI) Pharmacyclics LLC Genentech, Inc. University of California, Davis | Phase 2 |
| NCT04444622 | Immunotherapy for Third Line Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | Biological: AlloStim | Immunovative Therapies, Ltd. Mirror Biologics, Inc. | Phase 2 |
| NCT04442581 | Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | Advanced Hepatocellular Carcinoma BCLC Stage B Hepatocellular Carcinoma BCLC Stage C Hepatocellular Carcinoma | Drug: Cabozantinib S-malate Biological: Pembrolizumab | University of Washington National Cancer Institute (NCI) | Phase 2 |
| NCT04420754 | Study of AIC100 in Relapsed/Refractory Thyroid Cancer | Anaplastic Thyroid Cancer Relapsed/Refractory Poorly Differentiated Thyroid Cancer | Biological: AIC100 CAR T Cells | AfflyImmune Therapeutics, Inc. Weill Medical College of Cornell University | Phase 1 |
| NCT04407442 | Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab | Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma | Drug: Azacitidine Biological: Daratumumab Drug: Dexamethasone | University of California, San Francisco Janssen Pharmaceuticals | Phase 2 |

해외 바이오의약품 임상 현황 (2020.09.28~2020.10.04)

한국바이오의약품협회, 2020.10.6.
출처: ClinicalTrials.gov

| | | | | | |
|-------------|--|---|---|---|---------|
| NCT04395222 | Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation | Hematologic Malignancy Bone Marrow Transplant | Drug: Tocilizumab Drug: Fludarabine Drug: Melphalan Drug: Anti-thymocyte globulin (rabbit) Radiation: Total Body Irradiation | Weill Medical College of Cornell University | Phase 2 |
| NCT04388761 | Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI) | Ischemia Reperfusion Injury | Drug: Allogeneic adipose derived mesenchymal stem cells | Tambi Jarmi Mayo Clinic | Phase 2 |
| NCT04384692 | Ruxolitinib for the Treatment of Graft Versus Host Disease Following Stem Cell Transplant in Patients With Primary and Secondary Myelofibrosis | Primary Myelofibrosis Secondary Myelofibrosis | Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Busulfan Drug: Cyclophosphamide Drug: Fludarabine Drug: Melphalan Drug: Methotrexate Drug: Mycophenolate Mofetil Drug: Ruxolitinib Drug: Tacrolimus Radiation: Total-Body Irradiation | Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) | Phase 2 |
| NCT04375631 | CLAG-M Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia Recurrent Chronic Myelomonocytic Leukemia Recurrent Myelodysplastic Syndrome Refractory Acute Myeloid Leukemia Refractory Chronic Myelomonocytic Leukemia Refractory Mixed Phenotype Acute Leukemia Refractory Myelodysplastic Syndrome Refractory Acute Leukemia of Ambiguous Lineage Refractory Acute Undifferentiated Leukemia | Drug: Cladribine Drug: Cyclophosphamide Drug: Cyclosporine Drug: Cytarabine Biological: Filgrastim Procedure: Hematopoietic Cell Transplantation Drug: Mitoxantrone Drug: Mycophenolate Mofetil Drug: Mycophenolate Sodium Radiation: Total-Body Irradiation | Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) | Phase 1 |
| NCT04373642 | "QUAD SHOT" Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck Cancer | Head and Neck Cancer | Drug: Pembrolizumab + QUADSHOT Radiotherapy | University of Oklahoma | Phase 2 |
| NCT04372927 | ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy | Locally Advanced Lung Non-Small Cell Carcinoma Stage III Lung Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8 Stage IIIB Lung Cancer AJCC v8 Stage IIIC Lung Cancer AJCC v8 | Drug: Cisplatin Biological: Durvalumab Drug: Etoposide Radiation: Hypofractionated Radiation Therapy Drug: Pemetrexed | University of Washington National Cancer Institute (NCI) AstraZeneca | Phase 2 |
| NCT04370301 | Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis | Primary Myelofibrosis Secondary Myelofibrosis | Drug: Cyclophosphamide Drug: JAK Inhibitor Drug: Fludarabine Biological: Recombinant Granulocyte Colony-Stimulating Factor Drug: Melphalan Drug: Mycophenolate Mofetil Procedure: Peripheral Blood Stem Cell Transplantation Drug: Tacrolimus Radiation: Total-Body Irradiation | Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) | Phase 2 |
| NCT04362501 | Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) | Chronic Sinusitis | Biological: dupilumab Drug: placebo | Johns Hopkins University | Phase 2 |
| NCT04359784 | Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy | B-Cell Non-Hodgkin Lymphoma | Biological: Anakinra Biological: Axicabtagene Ciloleucel | Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) Sobi | Phase 2 |
| NCT04348747 | Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer | Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Malignant Neoplasm in the Brain Metastatic Triple-Negative Breast Carcinoma Prognostic Stage IV Breast Cancer AJCC v8 | Biological: Anti-HER2/HER3 Dendritic Cell Vaccine Drug: Celecoxib Biological: Pembrolizumab Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod | Roswell Park Cancer Institute National Cancer Institute (NCI) | Phase 2 |
| NCT04336943 | Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load | Biochemically Recurrent Prostate Carcinoma Prostate Adenocarcinoma | Biological: Durvalumab Drug: Olaparib Other: Quality-of-Life Assessment Other: Questionnaire Administration | University of Washington National Cancer Institute (NCI) AstraZeneca | Phase 2 |
| NCT04329065 | Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer | Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage IB Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 Prognostic Stage I Breast Cancer AJCC v8 Prognostic Stage IA Breast Cancer AJCC v8 Prognostic Stage IB Breast Cancer AJCC v8 Prognostic Stage II Breast Cancer AJCC v8 Prognostic Stage IIA Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Prognostic Stage III Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8 | Biological: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine Drug: Paclitaxel Biological: Trastuzumab Biological: Pertuzumab | University of Washington National Cancer Institute (NCI) United States Department of Defense | Phase 2 |
| NCT04301778 | Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma | Unresectable Intrahepatic Cholangiocarcinoma | Drug: Durvalumab Drug: SNDX-6532 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Syndax Pharmaceuticals AstraZeneca | Phase 2 |
| NCT04278924 | Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Participants With Persistent/Chronic Primary Immune Thrombocytopenia | Primary Immune Thrombocytopenia | Drug: Placebo Drug: TAK-079 | Millennium Pharmaceuticals, Inc. Takeda | Phase 2 |
| NCT04274166 | Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: secukinumab 150 mg (2 injections per dose) | Wake Forest University Health Sciences Novartis | Phase 2 |
| NCT04262167 | Human Autologous Lung Stem Cell Transplant for Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Biological: Lung Spheroid Stem Cells 100 million Biological: Lung Spheroid Stem Cells 200 million | University of North Carolina, Chapel Hill National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |

해외 바이오의약품 임상 현황 (2020.09.28~2020.10.04)

한국바이오의약품협회, 2020.10.6.
출처: ClinicalTrials.gov

| | | | | | |
|-------------|--|--|--|--|---------|
| NCT04254419 | Intra-tumoral Injection of Natural Killer Cells in High-Grade Gliomas | High Grade Glioma | Biological: NK cells | Nationwide Children's Hospital | Phase 1 |
| NCT04242264 | Phase 2 Shigella Vaccine and Challenge | Immunisation Shigella Infection | Other: Placebo Biological: Shigella sonnei strain 53G Biological: WRSs2 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| NCT04195633 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | Acute Leukemia Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Adult Diffuse Large Cell Lymphoma Anaplastic Large Cell Lymphoma Burkitt Lymphoma Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Myelomonocytic Leukemia Hodgkin Lymphoma Lymphoblastic Lymphoma Lymphoplasmacytic Lymphoma Mantle Cell Lymphoma Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Polymorphocytic Leukemia Refractory Chronic Lymphocytic Leukemia Refractory Follicular Lymphoma Refractory Marginal Zone Lymphoma Refractory Small Lymphocytic Lymphoma | Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Cyclophosphamide Drug: Cyclosporine Biological: Filgrastim Drug: Fludarabine Drug: Mycophenolate Mofetil Drug: Mycophenolate Sodium Radiation: Total-Body Irradiation Drug: Treosulfan | Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) | Phase 2 |
| NCT04190056 | Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer | Anatomic Stage IV Breast Cancer AJCC v8 Prognostic Stage IV Breast Cancer AJCC v8 | Biological: Pembrolizumab Drug: Tamoxifen Drug: Vorinostat | University of California, San Francisco Merck Sharp & Dohme Corp. | Phase 2 |
| NCT04177810 | Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer | Metastatic Pancreatic Cancer | Drug: Cemiplimab Drug: Plerixafor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Genzyme, a Sanofi Company American Association for Cancer Research | Phase 2 |
| NCT04161066 | Adjunctive Effects of Psilocybin and Buprenorphine | Opioid Use Disorder | Drug: Psilocybin with guided counseling | University of Wisconsin, Madison Heffter Research Institute | Phase 1 |
| NCT04149821 | Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy | Chronic Lymphocytic Leukemia CLL Progression CLL/SLL | Drug: Umbralisib Drug: Ublituximab | Weill Medical College of Cornell University TG Therapeutics, Inc. | Phase 2 |
| NCT04089579 | hCT-MSC in Children With Autism Spectrum Disorder | Autism Autism Spectrum Disorder | Biological: Cord Tissue Mesenchymal Stromal Cells Other: Placebo Infusion | Joanne Kurtzberg, MD The Marcus Foundation Duke University | Phase 2 |
| NCT04059757 | Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute GVHD | Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD) | Biological: Fecal Microbiota Transplantation (FMT) | Leland Metheny Case Comprehensive Cancer Center | Phase 2 |
| NCT04030052 | Emicizumab PUPs and Nuwiq ITI Study | Hemophilia A | Drug: Nuwiq (low dose protocol) Drug: HEMLIBRA Drug: Nuwiq (Atlanta protocol) | Emory University | Phase 3 |
| NCT04024878 | NeoVax With Nivolumab in Patients With Ovarian Cancer | Ovarian Cancer | Drug: Nivolumab Biological: NeoVax Procedure: Core Needle Biopsy | Dana-Farber Cancer Institute United States Department of Defense | Phase 1 |
| NCT03943901 | Split-Dose R-CHOP for Older Adults With DLBCL | Diffuse Large B Cell Lymphoma DLBCL Cancer | Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone Biological: Pegfilgrastim | University of Wisconsin, Madison Medical College of Wisconsin | Phase 2 |
| NCT03941769 | Recombinant Human Interleukin-7 to Promote T-Cell Recovery After Cord Blood Transplant | Acute Myeloid Leukemia Chronic Myelogenous Leukemia, BCR-ABL1 Positive Cord Blood Transplant Recipient Myelodysplastic Syndrome Myeloproliferative Neoplasm | Biological: Recombinant Interleukin-7 | M.D. Anderson Cancer Center National Cancer Institute (NCI) | Phase 1 |
| NCT03929029 | Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma | Melanoma | Drug: Nivolumab Biological: NeoVax plus Montanide Drug: Ipilimumab | Dana-Farber Cancer Institute National Cancer Institute (NCI) | Phase 1 |
| NCT03810911 | Mechanisms of EPO-induced Hypertension | Chronic Kidney Disease Blood Pressure Anemia | Drug: Darbepoetin | VA Office of Research and Development | Phase 2 |
| NCT03760575 | Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM) | Mesotheliomas Pleural | Drug: Pembrolizumab Procedure: Indocyanine Green (ICG) Image-Guided Surgery Drug: Cisplatin Drug: Pemetrexed | Abramson Cancer Center of the University of Pennsylvania | Phase 1 |
| NCT03602898 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation | Acute Lymphoblastic Leukemia in Remission Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Hematopoietic and Lymphoid System Neoplasm Myelodysplastic Syndrome Myelofibrosis Myeloproliferative Neoplasm Recurrent Acute Myeloid Leukemia Recurrent Hodgkin Lymphoma Recurrent Non-Hodgkin Lymphoma Refractory Acute Myeloid Leukemia Therapy-Related Acute Myeloid Leukemia | Biological: Anti-Thymocyte Globulin Drug: Busulfan Drug: Cyclophosphamide Drug: Cyclosporine Drug: Fludarabine Phosphate Drug: Methotrexate Procedure: Peripheral Blood Stem Cell Transplantation Other: Quality-of-Life Assessment Other: Questionnaire Administration Drug: Tacrolimus Radiation: Total-Body Irradiation | Fred Hutchinson Cancer Research Center | Phase 2 |
| NCT04526509 | Investigation of Autologous Enhanced T Cells in Advanced Tumors | Neoplasms | Drug: GSK3901961 Drug: GSK3845097 Drug: Fludarabine Drug: Cyclophosphamide | GlaxoSmithKline | Phase 1 |
| NCT04430738 | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers | Colorectal Carcinoma Gastric Adenocarcinoma Esophageal and GEJ Adenocarcinoma Cholangiocarcinoma Gallbladder Carcinoma | Drug: tucatinib Drug: trastuzumab Drug: oxaliplatin Drug: leucovorin Drug: fluorouracil | Seattle Genetics, Inc. | Phase 1 |
| NCT03980769 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders | Benign Neoplasm | Drug: Thiotepa Drug: Treosulfan Drug: Fludarabine Phosphate Biological: Rabbit Anti-Thymocyte Globulin Procedure: Allogeneic Hematopoietic Stem Cell Transplantation | Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| NCT04442230 | NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19) | Coronavirus Infection | Biological: NasoVAX Other: Placebo | Altimmune, Inc. | Phase 2 |

해외 바이오의약품 임상 현황 (2020.09.28~2020.10.04)

한국바이오의약품협회, 2020.10.6.
출처: ClinicalTrials.gov

| | | | | | |
|-------------|--|--|---|--|---------------------|
| NCT04216589 | Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) | HIV Infections Non-Alcoholic Fatty Liver Disease | Drug: Semaglutide | National Institute of Allergy and Infectious Diseases (NIAID) The University of Texas Health Science Center, Houston | Phase 2 |
| NCT04300140 | Efficacy and Safety Study of AVB-S6-500 in Patients With Clear Cell Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Drug: AVB-S6-500 Drug: Cabozantinib (Cabo) | Aravive, Inc. | Phase 1 Phase 2 |
| NCT04557384 | A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer | Advanced Solid Tumor | Drug: Ramucirumab | Eli Lilly and Company | Phase 1 |
| NCT04272645 | Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer | Prostate Cancer | Drug: Abemaciclib 200 MG Drug: Atezolizumab 1200 MG in 20 ML Injection Drug: Abemaciclib 150 MG | University of Michigan Rogel Cancer Center | Phase 2 |
| NCT04502888 | Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin | Cutaneous Squamous Cell Carcinoma Squamous Cell Carcinoma of Head and Neck | Drug: Drug: SL-172154 | Shattuck Labs, Inc. | Phase 1 |
| NCT04468971 | REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia | COVID19 ARDS | Biological: CK0802 Drug: Placebo | Cellenkos, Inc. | Phase 1 |
| NCT04544449 | A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Drug: fenebrutinib Drug: ocrelizumab Drug: placebo | Hoffmann-La Roche | Phase 3 |
| NCT04240704 | Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) | Non-Hodgkins Lymphoma Chronic Lymphocytic Leukemia | Drug: JBH492 | Novartis Pharmaceuticals Novartis | Phase 1 |
| NCT04543617 | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Drug: Tiragolumab Drug: Atezolizumab Drug: Tiragolumab Matching Placebo Drug: Atezolizumab Matching Placebo | Hoffmann-La Roche | Phase 3 |
| NCT04553770 | Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | Early-stage Breast Cancer Hormone Receptor Positive Breast Carcinoma Invasive Breast Cancer Stage II Breast Cancer Stage IIA Breast Cancer Stage IIB Breast Cancer Stage III Breast Cancer | Drug: Anastrozole Procedure: Therapeutic Conventional Surgery Biological: Trastuzumab Deruxtecan | Jonsson Comprehensive Cancer Center Translational Research in Oncology-U.S Daiichi Sankyo Co., Ltd. | Phase 2 |
| NCT04516278 | A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders | Age-related Macular Degeneration Neovascular Age-related Macular Degeneration Wet Macular Degeneration BRVO - Branch Retinal Vein Occlusion Diabetic Macular Edema | Biological: bevacizumab | Outlook Therapeutics, Inc. | Phase 3 |
| NCT04471428 | Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy | Carcinoma, Non-Small-Cell Lung | Drug: Cabozantinib Drug: Atezolizumab Drug: Docetaxel | Hoffmann-La Roche Exelixis | Phase 3 |
| NCT04432584 | A Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors. | Paroxysmal Nocturnal Hemoglobinuria | Drug: Crovalimab Drug: Eculizumab | Hoffmann-La Roche Chugai Pharmaceutical | Phase 3 |
| NCT04351230 | T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer | Anatomic Stage IV Breast Cancer AJCC v8 HER2 Positive Breast Carcinoma Metastatic Breast Carcinoma Prognostic Stage IV Breast Cancer AJCC v8 | Drug: Abemaciclib Biological: Trastuzumab Emtansine | Academic and Community Cancer Research United National Cancer Institute (NCI) | Phase 2 |
| NCT04495010 | Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants | Melanoma | Biological: Nivolumab Biological: Ipilimumab | Bristol-Myers Squibb | Phase 2 |
| NCT04171765 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis | Non-alcoholic Steatohepatitis | Drug: Placebo Drug: BFKB8488A | Genentech, Inc. | Phase 2 |
| NCT04516291 | A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70) | Dyslipidemias Hyperlipidemias Hyperlipoproteinemias | Drug: Vupanorsen Drug: Placebo | Pfizer TIMI Study Group | Phase 2 |
| NCT04464798 | A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas | Lymphoma | Drug: CC-220 Drug: Rituximab Drug: Obinutuzumab | Celgene | Phase 1 |
| NCT04560998 | A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes | Diabetes Mellitus, Type 2 Peripheral Arterial Disease | Drug: Semaglutide Drug: Placebo (semaglutide) | Novo Nordisk A/S | Phase 3 |
| NCT04515394 | Study of Tepotinib Combined With Cetuximab in Participants Left-Sided Metastatic Colorectal Cancer (mCRC) Acquired Resistance Due to Mesenchymal Epithelial Transition (MET) Amplification | Colorectal Neoplasms | Drug: Tepotinib Biological: Cetuximab | EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany EMD Serono | Phase 2 |

해외 바이오의약품 임상 현황 (2020.09.28~2020.10.04)

한국바이오의약품협회, 2020.10.6.
출처: ClinicalTrials.gov

○ 영국 6건

| NCT Number | Title | Conditions | Interventions | Sponsor/Collaborators | Phases |
|-------------|---|---|---|---|---------------------|
| NCT04458311 | Abiraterone Acetate in Combination With Tildrakizumab | Metastatic Castration Resistant Prostate Cancer | Drug: Abiraterone Acetate Drug: Tildrakizumab | Institute of Cancer Research, United Kingdom Sun Pharma Global FZE | Phase 1 Phase 2 |
| NCT04442022 | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Relapsed/Refractory Diffuse Large B-cell Lymphoma | Drug: Selinexor (combination therapy) Drug: Placebo matching for Selinexor (combination therapy) Drug: Rituximab (combination therapy) Drug: Gemcitabine (combination therapy) Drug: Dexamethasone (combination therapy) Drug: Cisplatin (combination therapy) Drug: Selinexor (continuous therapy) Drug: Placebo matching for Selinexor (continuous therapy) | Karyopharm Therapeutics Inc | Phase 2 Phase 3 |
| NCT04543617 | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Drug: Tiragolumab Drug: Atezolizumab Drug: Tiragolumab Matching Placebo Drug: Atezolizumab Matching Placebo | Hoffmann-La Roche | Phase 3 |
| NCT04471428 | Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy | Carcinoma, Non-Small-Cell Lung | Drug: Cabozantinib Drug: Atezolizumab Drug: Docetaxel | Hoffmann-La Roche Exelixis | Phase 3 |
| NCT04515394 | Study of Tepotinib Combined With Cetuximab in Participants Left-Sided Metastatic Colorectal Cancer (mCRC) Acquired Resistance Due to Mesenchymal Epithelial Transition (MET) Amplification | Colorectal Neoplasms | Drug: Tepotinib Biological: Cetuximab | EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany EMD Serono | Phase 2 |
| NCT04432584 | A Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors. | Paroxysmal Nocturnal Hemoglobinuria | Drug: Crovalimab Drug: Eculizumab | Hoffmann-La Roche Chugai Pharmaceutical | Phase 3 |

○ 프랑스 15건

| NCT Number | Title | Conditions | Interventions | Sponsor/Collaborators | Phases |
|-------------|--|---|---|---|---------------------|
| NCT03949881 | Cultured Autologous Oral Mucosa Epithelial Sheet for the Treatment of Bilateral Limbal Stem Cell Deficiency | Total Bilateral Limbal Cell Deficiency | Biological: FEMJA transplatation | Hospices Civils de Lyon | Phase 1 Phase 2 |
| NCT04515043 | EXPLORATORY STUDY Addendum to INVAC-1-CT-101 (NCT02301754) | Solid Tumor, Adult | Drug: INVAC-1 given in the previous phase 1 NCT02301754. No new injection is required in this study. | Invectys | Phase 1 |
| NCT04563923 | Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody | Bullous Pemphigoid | Drug: Avdoralimab (IPH5401) Other: Control | Centre Hospitalier Universitaire de Nice | Phase 2 |
| NCT04274023 | Study on TSR-042 in Advanced Clear Cell Sarcoma | Sarcoma, Clear Cell | Drug: TSR-042 | Italian Sarcoma Group GlaxoSmithKline | Phase 2 |
| NCT04262687 | Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate | Colorectal Cancer Metastatic High Immune Infiltrate Microsatellite Stable | Drug: Capecitabine Drug: Oxaliplatin Drug: Bevacizumab Drug: Pembrolizumab | Federation Francophone de Cancerologie Digestive | Phase 2 |
| NCT04108026 | Immunotherapy in Patient With Poor General Condition | Non-small Cell Lung Cancer Stage IV | Drug: Durvalumab | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 |
| NCT04543617 | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Drug: Tiragolumab Drug: Atezolizumab Drug: Tiragolumab Matching Placebo Drug: Atezolizumab Matching Placebo | Hoffmann-La Roche | Phase 3 |
| NCT04471428 | Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy | Carcinoma, Non-Small-Cell Lung | Drug: Cabozantinib Drug: Atezolizumab Drug: Docetaxel | Hoffmann-La Roche Exelixis | Phase 3 |
| NCT04464798 | A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas | Lymphoma | Drug: CC-220 Drug: Rituximab Drug: Obinutuzumab | Celgene | Phase 1 |
| NCT04515394 | Study of Tepotinib Combined With Cetuximab in Participants Left-Sided Metastatic Colorectal Cancer (mCRC) Acquired Resistance Due to Mesenchymal Epithelial Transition (MET) Amplification | Colorectal Neoplasms | Drug: Tepotinib Biological: Cetuximab | EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany EMD Serono | Phase 2 |
| NCT04495010 | Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants | Melanoma | Biological: Nivolumab Biological: Ipilimumab | Bristol-Myers Squibb | Phase 2 |
| NCT04171765 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis | Non-alcoholic Steatohepatitis | Drug: Placebo Drug: BFKB8488A | Genentech, Inc. | Phase 2 |

해외 바이오의약품 임상 현황 (2020.09.28~2020.10.04)

한국바이오의약품협회, 2020.10.6.
출처: ClinicalTrials.gov

| | | | | | |
|-------------|--|---|---|---|---------------------|
| NCT04432584 | A Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors. | Paroxysmal Nocturnal Hemoglobinuria | Drug: Crovalimab Drug: Eculizumab | Hoffmann-La Roche Chugai Pharmaceutical | Phase 3 |
| NCT04442022 | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Relapsed/Refractory Diffuse Large B-cell Lymphoma | Drug: Selinexor (combination therapy) Drug: Placebo matching for Selinexor (combination therapy) Drug: Rituximab (combination therapy) Drug: Gemcitabine (combination therapy) Drug: Dexamethasone (combination therapy) Drug: Cisplatin (combination therapy) Drug: Selinexor (continuous therapy) Drug: Placebo matching for Selinexor (continuous therapy) | Karyopharm Therapeutics Inc | Phase 2 Phase 3 |
| NCT04432389 | Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB [®]) Single Implantation in Tibial Fracture | Tibial Fracture | Biological: ALLOB Other: placebo | Bone Therapeutics S.A ICON plc | Phase 2 |

○ 독일 12건

| NCT Number | Title | Conditions | Interventions | Sponsor/Collaborators | Phases |
|-------------|--|---|---|--|---------------------|
| NCT04569383 | Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S Against COVID-19 | Covid19 | Biological: MVA-SARS-2-S vaccinations (days 0 & 28) | Universitätsklinikum Hamburg-Eppendorf German Center for Infection Research Philipps University Marburg Medical Center Ludwig-Maximilians - University of Munich | Phase 1 |
| NCT04522544 | Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design | Hepatocellular Carcinoma Non-resectable | Drug: Tremelimumab Drug: Durvalumab Procedure: Y-90 SIRT Procedure: TACE | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest AstraZeneca | Phase 2 |
| NCT04377334 | Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS) | ARDS COVID-19 | Biological: MSC | University Hospital Tuebingen | Phase 2 |
| NCT04278885 | Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS) | Hereditary Autoinflammatory Disease | Drug: Lanadelumab | Charite University, Berlin, Germany Shire International GmbH | Phase 2 |
| NCT03925194 | A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF | Cystic Fibrosis, 10011762 | Drug: Anakinra | Heidelberg University | Phase 2 |
| NCT04442022 | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Relapsed/Refractory Diffuse Large B-cell Lymphoma | Drug: Selinexor (combination therapy) Drug: Placebo matching for Selinexor (combination therapy) Drug: Rituximab (combination therapy) Drug: Gemcitabine (combination therapy) Drug: Dexamethasone (combination therapy) Drug: Cisplatin (combination therapy) Drug: Selinexor (continuous therapy) Drug: Placebo matching for Selinexor (continuous therapy) | Karyopharm Therapeutics Inc | Phase 2 Phase 3 |
| NCT04543617 | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Drug: Tiragolumab Drug: Atezolizumab Drug: Tiragolumab Matching Placebo Drug: Atezolizumab Matching Placebo | Hoffmann-La Roche | Phase 3 |
| NCT04560998 | A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes | Diabetes Mellitus, Type 2 Peripheral Arterial Disease | Drug: Semaglutide Drug: Placebo (semaglutide) | Novo Nordisk A/S | Phase 3 |
| NCT04471428 | Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy | Carcinoma, Non-Small-Cell Lung | Drug: Cabozantinib Drug: Atezolizumab Drug: Docetaxel | Hoffmann-La Roche Exelixis | Phase 3 |
| NCT04464798 | A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas | Lymphoma | Drug: CC-220 Drug: Rituximab Drug: Obinutuzumab | Celgene | Phase 1 |
| NCT04432584 | A Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors. | Paroxysmal Nocturnal Hemoglobinuria | Drug: Crovalimab Drug: Eculizumab | Hoffmann-La Roche Chugai Pharmaceutical | Phase 3 |
| NCT04495010 | Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants | Melanoma | Biological: Nivolumab Biological: Ipilimumab | Bristol-Myers Squibb | Phase 2 |

해외 바이오의약품 임상 현황 (2020.09.28~2020.10.04)

한국바이오의약품협회, 2020.10.6.
출처: ClinicalTrials.gov

○ 중국 17건

| NCT Number | Title | Conditions | Interventions | Sponsor/Collaborators | Phases |
|-------------|--|---|--|---|---------------------|
| NCT04551547 | Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19 | COVID-19 | Biological: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 Other: Two doses of placebo at the schedule of day 0,28 | Sinovac Research and Development Co., Ltd. Sinovac Biotech Co., Ltd | Phase 1 Phase 2 |
| NCT04570410 | Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma | Bladder Urothelial Carcinoma | Procedure: primary focal resection plus lymph node dissection Drug: Tislelizumab Drug: Gemcitabine plus cisplatin | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| NCT04562298 | A Single-Center, Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer | Epithelial Ovarian Cancer | Biological: LCAR-M23 cells | Shanghai East Hospital Nanjing Legend Biotech Co., Ltd East Clinical Center of Oncology | Phase 1 |
| NCT04556071 | Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer | Ovarian Neoplasms Fallopian Tube Neoplasms Endocrine Gland Neoplasms Neoplasms by Site Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Carcinoma, Ovarian Epithelial Ovarian Diseases Adnexal Diseases Genital Diseases, Female Endocrine System Diseases Gonadal Disorders Carcinoma Bevacizumab Enzyme Inhibitors Antineoplastic Agents Molecular Mechanisms of Pharmacological Action Angiogenesis BRCA1 Mutation BRCA2 Mutation Homologous Recombination Deficiency | Drug: Niraparib Drug: Bevacizumab | Xiaoxiang Chen Jiangsu Cancer Hospital (Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital) | Phase 2 |
| NCT04552366 | A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults | COVID-19 | Biological: Ad5-nCoV | Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China Zhongnan Hospital | Phase 1 |
| NCT04528550 | Autologous Bone Marrow-derived Mononuclear Cells for Acute Spinal Cord Injury | Spinal Cord Injury | Biological: Autologous bone marrow-derived mononuclear cells Drug: Placebo | Shanghai Changzheng Hospital | Phase 2 |
| NCT04524884 | Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study | Thyroid Cancer | Drug: Surufatinib Drug: Toripalimab | Fudan University | Phase 2 |
| NCT04521179 | Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors | HER2-positive Solid Tumors | Drug: KN026 combination | Jiangsu Alphamab Biopharmaceuticals Co., Ltd Peking University | Phase 2 |
| NCT04270461 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | Hepatocellular Carcinoma Glioblastoma Medulloblastoma Colon Cancer | Biological: NKG2D-based CAR T-cells | Jiujiang University Affiliated Hospital KAEDI | Phase 1 |
| NCT04221971 | NK Cell Infusion for Patients With Acute Myeloid Leukemia | Acute Myeloid Leukemia | Drug: chemotherapy combined with NK cells infusion | Peking University People's Hospital The University of Science and Technology of China | Phase 1 |
| NCT04557020 | Adding Neoadjuvant and Adjuvant PD-1 Inhibitor to Neoadjuvant Chemotherapy Plus Concurrent Chemoradiotherapy in the Treatment of High-risk Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | Drug: PD-1 antibody Drug: Gemcitabine Drug: cis Platinum Radiation: IMRT | Jiangxi Provincial Cancer Hospital | Phase 3 |
| NCT04531865 | Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment | Frequently Relapsing Nephrotic Syndrome Steroid-Dependent Nephrotic Syndrome | Drug: Rituximab Drug: Mycophenolate Mofetil Drug: Placebo tablets matching Mycophenolate Mofetil | Children's Hospital of Fudan University Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Shanghai Children's Medical Center Shanghai Children's Hospital | Phase 3 |
| NCT04535518 | Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease | Kawasaki Disease | Drug: IVIG Drug: Aspirin Drug: Infliximab | Children's Hospital of Fudan University Shanghai Children's Hospital Shanghai Children's Medical Center Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Shanghai 10th People's Hospital | Phase 3 |
| NCT04574284 | A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer | Advanced Endometrial Cancer | Drug: TQB2450 Drug: Anlotinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| NCT04456387 | An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A | Hemophilia A | Drug: Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection | Zhengzhou Gensciences Inc Haimen Gensciences Inc | Phase 3 |
| NCT04543617 | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Drug: Tiragolumab Drug: Atezolizumab Drug: Tiragolumab Matching Placebo Drug: Atezolizumab Matching Placebo | Hoffmann-La Roche | Phase 3 |

해외 바이오의약품 임상 현황 (2020.09.28~2020.10.04)

한국바이오의약품협회, 2020.10.6.
출처: ClinicalTrials.gov

| | | | | | |
|-------------|---|------------------------------------|---|-------------|---------|
| NCT04550260 | Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC | Esophageal Squamous Cell Carcinoma | Drug: Durvalumab Drug: Placebo Drug: cisplatin + fluorouracil Drug: cisplatin + capecitabine Radiation: Radiation | AstraZeneca | Phase 3 |
|-------------|---|------------------------------------|---|-------------|---------|

○ 일본 6건

| NCT Number | Title | Conditions | Interventions | Sponsor/Collaborators | Phases |
|-------------|---|---|---|---|---------|
| NCT04543617 | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Drug: Tiragolumab Drug: Atezolizumab Drug: Tiragolumab Matching Placebo Drug: Atezolizumab Matching Placebo | Hoffmann-La Roche | Phase 3 |
| NCT04432584 | A Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors. | Paroxysmal Nocturnal Hemoglobinuria | Drug: Crovalimab Drug: Eculizumab | Hoffmann-La Roche Chugai Pharmaceutical | Phase 3 |
| NCT04560998 | A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes | Diabetes Mellitus, Type 2 Peripheral Arterial Disease | Drug: Semaglutide Drug: Placebo (semaglutide) | Novo Nordisk A/S | Phase 3 |
| NCT04471428 | Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy | Carcinoma, Non-Small-Cell Lung | Drug: Cabozantinib Drug: Atezolizumab Drug: Docetaxel | Hoffmann-La Roche Exelixis | Phase 3 |
| NCT04240704 | Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) | Non-Hodgkins Lymphoma Chronic Lymphocytic Leukemia | Drug: JBH492 | Novartis Pharmaceuticals Novartis | Phase 1 |
| NCT04550260 | Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC | Esophageal Squamous Cell Carcinoma | Drug: Durvalumab Drug: Placebo Drug: cisplatin + fluorouracil Drug: cisplatin + capecitabine Radiation: Radiation | AstraZeneca | Phase 3 |